Markets GILD

Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline

April 09, 2026 — 09:16 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its oncology pipeline.

As per the expanded agreement, Tempus AI will provide enterprise-wide access to its AI-driven Lens platform, unlocking access to broader datasets across multiple indications and integrating dedicated Tempus analytical services.

The combination of Gilead's scientific expertise with Tempus' real world data insights in oncology is expected to maximize generation of key insights.

Ryan Fukushima, CEO of Tempus Data & Apps said, "We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights. This approach helps navigate billions of data points to find the 'signal in the noise,' ultimately increasing the probability of success for life-altering medicines."

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
GILD
TEM

Latest Articles
Data is currently not available